Fig. 4.

HER2-CRB enhances HER2-TDB-mediated T cell activation and cytotoxic activity. A Fold-change of luciferase activity normalized to untreated Jurkat-NKG2D + NFAT-Luc cells. Jurkat cells were co-cultured with BT474 cells for 6 h with either HER2.2C4-TDB or HER2-TDB or NIST-TDB in combination with either HER2-CRB or controls. B BT474 target cell killing normalized to time 0 h. BT474 cells were co-cultured for over five days with primary CD8 + T cells at an E:T ratio of 1:1 in the presence of 10 ng/ml of HER2-2C4-TDB alone or in combination with titrated HER2-CRB. Representative of four independent donors. C Cytokine quantification of CD8 + T cell and BT474 cell co-culture at an E:T of 1:1 in the presence of 10 ng/ml of HER2.2C4-TDB alone or in combination with HER2-CRB after 96 h. D Differential gene expression analysis from bulk RNA-seq on CD8 + T cells co-cultured for 24 h with BT474 cells in the presence of 10 ng/mL of HER2.2C4-TDB alone or in combination with HER2-CRB represented as a volcano plot. Blue dots represent Log(fold-change) of  ≤ -0.7 and red dots depict Log(fold-change) ≥ 0.7, p ≤ 0.05. Black points are below stated thresholds. E GSEA data from Hallmark (top) and Reactome (bottom) gene sets from results in (D). F GSEA from immunologic gene sets (C7) from data in (D)